Edgar Filing: THERMO FISHER SCIENTIFIC INC. - Form FWP

THERMO FISHER SCIENTIFIC INC.

Form FWP

December 05, 2013

Filed Pursuant to Rule 433

Registration No. 333-187080

Thermo Fisher Scientific Inc.

Term Sheet

December 4, 2013

4.15% Senior Notes due 2024

Issuer: Thermo Fisher Scientific Inc.

Principal Amount: \$1,000,000,000

Maturity Date: February 1, 2024

Coupon (Interest Rate): 4.150%

Yield to Maturity: 4.182%

Benchmark Treasury: 2.750% due November 2023

Spread to Benchmark Treasury: T + 135 bps

Benchmark Treasury Price and

Yield: 99-09+/2.832%

Interest Payment Dates: February 1 and August 1, commencing on August 1, 2014

Redemption Provision: Prior to November 1, 2023, we may redeem at our option the notes, in whole at

any time or in part from time to time, at a redemption price equal to the greater of (1) 100% of the principal amount of the notes to be redeemed and (2) the sum of the present values of the remaining scheduled payments of principal and interest in respect of the notes being redeemed (not including any portion of the payments of interest accrued but unpaid as of the date of redemption) discounted on a semi-annual basis (assuming a 360-day year of twelve 30-day months), at the Treasury Rate plus 20 basis points, plus accrued and unpaid interest, if any, to, but excluding, the date of redemption. In addition, on or after November 1, 2023, we may redeem at our option the notes, in whole at any time or in part from time to time, at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid

interest, if any, to, but excluding, the date of redemption.

Edgar Filing: THERMO FISHER SCIENTIFIC INC. - Form FWP

Special Mandatory Redemption: In the event that we do not consummate the Life Technologies Acquisition on

or prior to July 14, 2014 or the Merger Agreement is terminated at any time prior to such date, we will be required to redeem all of the notes on a special mandatory redemption date at a redemption price equal to 101% of the aggregate principal amount of the notes, plus accrued and unpaid interest, if

any, to, but excluding, the date of redemption.

Issue Price: 99.730%

Settlement Date: December 11, 2013 (T+5)

Current Ratings*: Moody s: Baa3 (stable)

S&P: BBB (watch negative)

Fitch: BBB (negative)

CUSIP: 883556BF8

ISIN: US883556BF82

Joint Book-Running Managers: Barclays Capital Inc.

J.P. Morgan Securities LLC

RBS Securities Inc.

Citigroup Global Markets Inc.

Credit Suisse Securities (USA) LLC

HSBC Securities (USA) Inc.

Merrill Lynch, Pierce Fenner & Smith

Incorporated

Morgan Stanley & Co. LLC

Co-Managers: Banca IMI S.p.A.

BNP Paribas Securities Corp.

BNY Mellon Capital Markets, LLC

Goldman, Sachs & Co.

ING Financial Markets LLC

KeyBanc Capital Markets Inc.

Mitsubishi UFJ Securities (USA), Inc.

Edgar Filing: THERMO FISHER SCIENTIFIC INC. - Form FWP

Mizuho Securities USA Inc.

Scotia Capital (USA) Inc.

SMBC Nikko Securities America, Inc.

U.S. Bancorp Investments, Inc.

^{*} A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. Credit ratings are subject to change depending on financial and other factors. On December 4, 2013, S&P announced that it would resolve its negative Creditwatch listing following its review of the impact of the final financing structure for Thermo Fisher Scientific Inc. s pending acquisition of Life Technologies Corporation on Thermo Fisher Scientific Inc. s financial risk profile.

The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the active joint book-running managers can arrange to send you the prospectus if you request it by calling Barclays Capital Inc. at 1-888-603-5847; or by calling J.P. Morgan Securities LLC at 1-212-834-4533; or by calling RBS Securities Inc. at 1-866-884-2071.